Methods of Reducing the Risk of Mortality Associated With a Medical Treatment
Disclosed are methods of treatment that permit a reduction of risk of mortality in infants who are candidates for treatment with inhaled nitric oxide, by identifying a subset of such infants who are at an increased risk of mortality upon treatment with inhaled nitric oxide; also disclosed are related systems for use in administering inhaled nitric oxide and methods of distributing a pharmaceutical product.
1 - 42 . (canceled)
43 . A method of treatment comprising
(a) identifying a plurality of neonates as being candidates for treatment with inhaled nitric oxide;
(b) determining that the race of a first neonate of the plurality is non-white;
(c) administering inhaled nitric oxide to the first neonate;
(d) determining that the race of a second neonate of the plurality is white;
(e) determining that the gender of the second neonate is male;
(f) determining that the second neonate is of less than 27 weeks post-menstrual age;
(g) determining that the fact that the second neonate is a white male of less than 27 weeks post-menstrual age means the second neonate is at a higher risk of mortality upon administration of inhaled nitric oxide compared to a female or non-white male neonate of the same post-menstrual age; and
(h) administering to the second neonate a treatment that comprises mechanical ventilation or positive airway pressure support while excluding the second neonate from treatment with inhaled nitric oxide, the exclusion from treatment with inhaled nitric oxide being based on the determination of (g).
44 . The method of claim 43 , wherein the second neonate does not have pulmonary hypertension.
45 . The method of claim 43 , wherein the second neonate is identified as being at risk of developing bronchopulmonary dysplasia (BPD).
46 . The method of claim 43 , wherein determining that the race of the second neonate is white comprises (i) visually assessing the race of the second neonate, or (ii) querying a relative of the second neonate about the race of the second neonate, or (iii) both (i) and (ii).
47 . The method of claim 43 , wherein the second neonate does not have left ventricular dysfunction and is not identified as being dependent on right-to-left shunting of blood.
48 . The method of claim 43 , wherein the treatment administered to the second neonate further comprises administration of a surfactant.
49 . The method of claim 43 , wherein the treatment administered to the second neonate further comprises extra-corporeal membrane oxygenation (ECMO).
50 . The method of claim 63 , wherein the second neonate is treated with ECMO after being excluded from treatment with inhaled nitric oxide.